MedTrace Logo

Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy

NCT00299884 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2016-03-29

No results posted yet for this study

Summary

The primary aim of this study is to evaluate the efficacy and non-inferiority of a lipid-lowering medication regimen comprised of the medications ezetimibe and fenofibrate taken daily, versus atorvastatin daily in lowering levels of low-density lipoprotein (LDL-C) cholesterol. Additionally, other aims would include effects on other types of blood cholesterol and examining the safety of the ezetimibe and fenofibrate regimen, as compared to atorvastatin.

Conditions

Interventions

DRUG

Lipitor 20 mg

A/A for 6 weeks

DRUG

Combination Ezetrol 10 mg and Lipidil Supra 160 mg

a/a for 6 weeks

Sponsors & Collaborators

  • Queen's University

    lead OTHER

Principal Investigators

  • Stephen A LaHaye, MD · Vascular Disease Prevention and Research Centre

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2006-07-31
Completion
2006-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00299884 on ClinicalTrials.gov